Humacyte, Inc.(HUMA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,922 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
HUMA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Humacyte, Inc. (HUMA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HUMA at 9.1/100 on a 32-signal composite quality model, placing it at rank #2,922 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.7) and revenue scale (0.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Humacyte, Inc. reports quarterly revenue of $406.0K, net income of $-36.8M, free cash flow of $-22.2M. Top institutional holders of HUMA by reported 13-F value include ANTIPODES PARTNERS Ltd, VANGUARD CAPITAL MANAGEMENT, Alyeska Investment Group, L.P., based on the most recent SEC filings. HUMA trades on the Nasdaq exchange and files with the SEC under CIK 1818382. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HUMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Humacyte, Inc. directly from SEC EDGAR. Humacyte, Inc.'s 13F Pro composite quality score has ranged between 9 and 13 since 2026, currently 9.1 — a stable long-term trajectory across 25 quarterly and live scoring snapshots.
Revenue
Q2 2026
$406.0K
Net Income
Q2 2026
$-36.8M
Free Cash Flow
Q2 2026
$-22.2M
D/E Ratio
Q2 2026
1.16
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+72.5% YoYOperating Income
+5.5% YoYEPS (Diluted)
+79.4% YoYTotal Assets
-15.6% YoYTotal Debt
Op. Cash Flow
-7.1% YoYFree Cash Flow
-6.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $0.00 | — | — | — | — |
| Net Income | $-40.8M +72.5% | $-148.7M -34.2% | $-110.8M -825.8% | $-12.0M +54.8% | $-26.5M +60.2% | $-66.5M |
| Operating Income | $-108.1M +5.5% | $-114.4M -14.3% | $-100.0M -18.3% | $-84.6M -4.1% | $-81.2M -25.7% | $-64.6M |
| EPS (Diluted) | $-0.26 +79.4% | $-1.26 -17.8% | $-1.07 -791.7% | $-0.12 +81.8% | $-0.66 +94.3% | $-11.54 |
| Total Assets | $116.4M -15.6% | $137.9M +7.5% | $128.2M -37.2% | $204.3M -28.7% | $286.5M +168.6% | $106.7M |
| Total Debt | $35.4M | $0.00 | — | — | $30.0M | — |
| Operating Cash Flow | $-105.0M -7.1% | $-98.1M -33.9% | $-73.3M -3.1% | $-71.1M +12.4% | $-81.2M -46.1% | $-55.6M |
| Free Cash Flow | $-105.9M -6.3% | $-99.7M -31.9% | $-75.6M -4.7% | $-72.2M +11.3% | $-81.4M -45.7% | $-55.9M |
Get alerted when HUMA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Humacyte, Inc. including:
Top Institutional Holders of HUMA
ANTIPODES PARTNERS Ltd
$7.9M10,103,647 shVANGUARD CAPITAL MANAGEMENT LLC
$7.9M10,107,679 shAlyeska Investment Group, L.P.
$4.7M6,022,925 shDAVIDSON KEMPNER CAPITAL MANAGEMENT LP
$3.9M5,000,000 shBlackRock, Inc.
$3.8M4,839,929 shGREAT POINT PARTNERS LLC
$2.9M3,750,000 shUBS Group AG
$2.2M2,843,493 shAQR CAPITAL MANAGEMENT LLC
$2.0M2,597,134 shGEODE CAPITAL MANAGEMENT, LLC
$1.7M2,185,225 shMILLENNIUM MANAGEMENT LLC
$1.5M1,909,049 sh
| Fund | Value | Shares |
|---|---|---|
| ANTIPODES PARTNERS Ltd | $7.9M | 10,103,647 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.9M | 10,107,679 |
| Alyeska Investment Group, L.P. | $4.7M | 6,022,925 |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | $3.9M | 5,000,000 |
| BlackRock, Inc. | $3.8M | 4,839,929 |
| GREAT POINT PARTNERS LLC | $2.9M | 3,750,000 |
| UBS Group AG | $2.2M | 2,843,493 |
| AQR CAPITAL MANAGEMENT LLC | $2.0M | 2,597,134 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.7M | 2,185,225 |
| MILLENNIUM MANAGEMENT LLC | $1.5M | 1,909,049 |
Companies Similar to HUMA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
IDEAYA Biosciences, Inc.
Silence Therapeutics plc
Evommune, Inc.
PRECISION BIOSCIENCES INC
MAXCYTE, INC.
DBV Technologies S.A.
uniQure N.V.
Pulmonx Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put HUMA on your watchlist
Track score changes the day Humacyte, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is HUMA a good stock to buy?
13F Pro's AI-powered analysis of Humacyte, Inc. (HUMA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HUMA are available on the HUMA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HUMA is classified as a small company.
Which hedge funds own HUMA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HUMA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Humacyte, Inc.'s investment landscape.